2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2474

Patients’ Experiences of Using a Smartphone App for Remote Monitoring of Rheumatoid Arthritis, Integrated into the Electronic Medical Record, and Its Impact on Consultations
Abstract Number: 2475

Identifying Key Variables for Inclusion in a Smartphone App to Support Clinical Care and Research in Patients with Rheumatoid Arthritis
Abstract Number: 2476

Performance of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) Appears to be Better Than Gold Standard Disease Assessment Score (DAS-28 CRP)
Abstract Number: 2477

Short Term Clinical Response to Initial Treatment with High Versus Low Dose Methotrexate in Mono- and Combination Therapy in Early Rheumatoid Arthritis Patients
Abstract Number: 2478

Impact of Poor Prognostic Factors on Treatment Decisions in Clinical Practice in Patients with Rheumatoid Arthritis: Findings from a US Observational Cohort
Abstract Number: 2479

Work Productivity in Early Rheumatoid Arthritis Patients Treated before and after Implementation of a Treat-to-Target Strategy
Abstract Number: 2480

Dose-Related Short Term Clinical Response to Initial Treatment with Methotrexate in Mono- and Combination Therapy in Early Rheumatoid Arthritis Patients – a Meta-Regression Analysis
Abstract Number: 2481

Infliximab Low Levels at Early Stages Predict the Loss of Drug Levels and the Clinical Response at One Year of Treatment in Patients with Rheumatoid Arthritis
Abstract Number: 2482

Long Term Drug Survival of Adalimumab and Etanercept Treatment for Rheumatoid Arthritis with and without Methotrexate
Abstract Number: 2483

Results of a Pilot Study of a Tailored Symptom Assessment Tool to Enhance Patient-Centered Care in Rheumatoid Arthritis: Choice RA
Abstract Number: 2484

Real World Treat to Target Strategy in Rheumatoid Arthritis: Radiograph and MRI Outcomes in Three Cohorts with 18 Month Follow up
Abstract Number: 2485

Correlates of Successful Flare Management: The Role of Clinician-Driven Treatment, Home-Based Strategies, and Medication Change
Abstract Number: 2486

Effect of a Dynamic Exercise Program in Combination with a Mediterranean Diet in Strength, Joint Mobility and Disease Activity in Women with Rheumatoid Arthritis
Abstract Number: 2487

In Patients with Rheumatoid Arthritis in Clinical Remission Undergoing Treatment Tapering Tenosynovitis and Synovitis Detected By Ultrasonography Predict Disease Flare
Abstract Number: 2488

A Randomised Controlled Trial Evaluating the Effect of Adalimumab upon Biomarkers of Cardiovascular Risk in ACPA-Positive Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].